Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Quality of life not reported · Patients with refractory/relapsed Hodgkin lymphoma High‐dose chemotherapy followed by autologous stem cell transplantation for patients with… (2013) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Overall survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 892 participants | Low |
Intervention NR Subgroup analysis in pediatric patients: Overall survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 133 participants | Low |
Intervention NR Subgroup analysis in pediatric patients: Disease‐free survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 127 participants | Low |
Intervention NR Disease‐free survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 1209 participants | High |
Intervention NR Adverse events requiring discontinuation [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 906 participants | Moderate |
Intervention NR Relapse rate [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 896 participants | Moderate |
Intervention NR Overall survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 632 participants | Moderate |
Intervention NR Disease‐free survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 670 participants | High |
Intervention NR Relapse rate [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 425 participants | Moderate |
Intervention NR Overall survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 1033 participants | Moderate |
Intervention NR Disease‐free survival [range of median · patients with APL in first complete remission The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission (2013) · Cochrane | no estimate extracted | 1028 participants | High |
Intervention NR Overall survival · patients with cancer Erythropoietin or darbepoetin for patients with cancer (2012) · Cochrane | HR 1.05 [1, 1.11] | 78 studies · 19003 participants | High |
Intervention NR On‐study mortality Death occurring up to 30 days after active study protocol · patients with cancer Erythropoietin or darbepoetin for patients with cancer (2012) · Cochrane | HR 1.17 [1.06, 1.29] | 70 studies · 15935 participants | High |
Intervention NR Thrombotic events · patients with cancer Erythropoietin or darbepoetin for patients with cancer (2012) · Cochrane | RR 1.52 [1.33, 1.73] | 57 studies · 15278 participants | Moderate |
Intervention NR Quality of Life ‐ Change in FACT‐Fatigue (13 items) FACT‐F 13 sub‐scale · patients with cancer Erythropoietin or darbepoetin for patients with cancer (2012) · Cochrane | no estimate extracted | 18 studies · 4965 participants | Low |
Intervention NR Quality of Life ‐ Change in FACT‐Anaemia (20 items) FACT‐An 20 · patients with cancer Erythropoietin or darbepoetin for patients with cancer (2012) · Cochrane | no estimate extracted | 6 studies · 1085 participants | Low |
Intervention NR Participants receiving red blood cell transfusions · patients with cancer Erythropoietin or darbepoetin for patients with cancer (2012) · Cochrane | RR 0.65 [0.62, 0.68] | 70 studies · 15877 participants | Moderate |
Prophylactic platelet transfusion vs non prophylactic or therapeutic platelet transfusion Bleeding: Numbers of patients with at least one significant bleeding event · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.66 [0.9, 3.04] | 1 study · 56 participants | Low |
Prophylactic platelet transfusion with one dose schedule vs prophylactic platelet transfusions with another dose schedule Bleeding Number of participants with a significant bleeding event ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.02 [0.93, 1.11] | 2 studies · 951 participants | High |
Prophylactic platelet transfusion with one dose schedule vs prophylactic platelet transfusions with another dose schedule Bleeding Number of days with significant bleeding ‐ Low dosage platelet transfusions versus standard dosage platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | no estimate extracted | 3 studies · 3 participants | Ungraded |
Prophylactic platelet transfusion with one dose schedule vs prophylactic platelet transfusions with another dose schedule Bleeding: Number of days with significant bleeding ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | no estimate extracted | 0 studies · 2 participants | Ungraded |
Prophylactic platelet transfusion with one dose schedule vs prophylactic platelet transfusions with another dose schedule Mortality:secondary to bleeding ‐ Low dosage platelet transfusions versus standard dose platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | no estimate extracted | 3 studies · 859 participants | Low |
Prophylactic platelet transfusion with one dose schedule vs prophylactic platelet transfusions with another dose schedule Mortality: secondary to bleeding ‐ High dosage platelet transfusions versus standard dosage platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.47 [0.06, 35.9] | 2 studies · 739 participants | Moderate |
Prophylactic platelet transfusion vs platelet‐poor plasma Number of participants with a significant bleeding event · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 0.47 [0.23, 0.95] | 1 study · 21 participants | Very low |
Prophylactic platelet transfusion vs platelet‐poor plasma Mortality: secondary to bleeding · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 2.31 [0.1, 50.85] | 1 study · 21 participants | Very low |
Prophylactic platelet transfusion vs platelet‐poor plasma Number of platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | no estimate extracted | 0 studies · 1 participants | Very low |
Prophylactic platelet transfusion vs non prophylactic or therapeutic platelet transfusion Bleeding: Number of days on which a significant bleeding event occurred3 · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 0.9 [0.62, 1.32] | 1 study · 342123 participants | Low |
Prophylactic platelet transfusion vs non prophylactic or therapeutic platelet transfusion Mortality: Secondary to bleeding · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.08 [0.23, 5.06] | 2 studies · 85 participants | Low |
Prophylactic platelet transfusion vs non prophylactic or therapeutic platelet transfusion Number of platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | no estimate extracted | 2 studies · 85 participants | Moderate |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Bleeding: Numbers of patients with at least one significant bleeding event · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.35 [0.95, 1.9] | 3 studies · 499 participants | Moderate |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Bleeding: Number of days on which clinically significant bleeding occurred5 · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.72 [1.33, 2.22] | 2 studies · 94205 participants | Moderate |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Mortality: secondary to bleeding · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 2.67 [0.11, 64.91] | 3 studies · 499 participants | Low |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Number of platelet transfusions per patient · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | no estimate extracted | 2 studies · 333 participants | Moderate |
Prophylactic platelet transfusion with one dose schedule vs prophylactic platelet transfusions with another dose schedule Bleeding: Number of participants with a significant bleeding event ‐ Low dosage platelet transfusions versus standard dosage platelet transfusions · Patients with a haematological disorder Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after… (2012) · Cochrane | RR 1.04 [0.95, 1.13] | 3 studies · 1070 participants | High |
Intervention NR Overall survival · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | HR 0.97 [0.76, 1.22] | 3 studies · 701 participants | Moderate |
Intervention NR Treatment‐related mortality · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | RR 1.28 [0.25, 6.61] | 4 studies · 941 participants | Moderate |
Intervention NR Progression‐free survival · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | HR 0.42 [0.33, 0.54] | 3 studies · 540 participants | Moderate |
Intervention NR Secondary malignancies AML/MDS · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | RR 2.87 [0.7, 11.75] | 4 studies · 1023 participants | Low |
Intervention NR Secondary malignancies Solid cancer · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | RR 1.2 [0.25, 5.77] | 3 studies · 701 participants | Low |
Intervention NR Adverse events · Adult patients with follicular lymphoma High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for… (2012) · Cochrane | no estimate extracted | 3 studies · 527 participants | Very low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Overall survival (median 2 years) · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.65 [0.45, 0.94] | 1 study · 335 participants | Moderate |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Treament related mortality · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 3.2 [0.66, 15.5] | 2 studies · 177 participants | Low |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Complete response rate · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 0.85 [0.67, 1.08] | 2 studies · 170 participants | Moderate |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Progression free survival (median 2 years) · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.61 [0.47, 0.81] | 2 studies · 356 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Treatment related mortality · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 0.57 [0.17, 1.9] | 2 studies · 356 participants | Moderate |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Cytomegalovirus reactivation · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 10.52 [1.42, 77.68] | 2 studies · 350 participants | High |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Complete response rate · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 2.61 [1.26, 5.42] | 2 studies · 356 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Infections (all grades) · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.32 [1.01, 1.74] | 2 studies · 356 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Serious adverse events · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.34 [0.95, 1.89] | 2 studies · 350 participants | Moderate |